Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635879 | 1.00 | TRPV1 (1.00) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL29389124 | 1.00 | TRPV1 (1.00) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL4262912 | 0.88 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL4265025 | 0.81 | TRPV1 (0.78) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL14422335 | 0.79 | TRPV1 (0.65) | TRPV1 | |
| SCHEMBL4262793 | 0.78 | TRPV1 (0.82) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL3712104 | 0.77 | TRPV1 (0.80) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL4269392 | 0.77 | TRPV1 (0.73) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL16690819 | 0.77 | TRPV1 (0.66) | TRPV1GAANPSR1HSD17B10CA12 | |
| SCHEMBL3095680 | 0.76 | HSD11B1 (0.76) | TRPV1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241442-B2 | Methods of use for TRP channel antagonist-based combination cancer therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210128581-A1 | METHODS OF USE FOR TRP CHANNEL ANTAGONIST-BASED COMBINATION CANCER THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-05-06 | — | — | US | disclosed |
| US-20200215085-A1 | Method to Abate Acute Airway Hypersensitivity and Asthma Attacks | AAZEINTX INC. (CA) | 2020-07-09 | — | — | US | disclosed |
| US-9642859-B2 | Use of capsazepine and analogs thereof to treat cancer | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642859-B2 | Use of capsazepine and analogs thereof to treat cancer | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-05-09 | — | — | US | disclosed |
| US-20150352123-A1 | USE OF CAPSAZEPINE AND ANALOGS THEREOF TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-12-10 | — | — | US | disclosed |
| US-20150352123-A1 | USE OF CAPSAZEPINE AND ANALOGS THEREOF TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-12-10 | — | — | US | disclosed |
| EP-2646107-A2 | AGENT DELIVERY SYSTEMS FOR SELECTIVE NEUROMODULATION | Spinal Modulation Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075337-A2 | DIRECTED DELIVERY OF AGENTS TO NEURAL ANATOMY | SPINAL MODULATION, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | disclosed |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | FAAH, FAAH2, TRPV1 | TRPV1 3/4885GAA 1309/4885NPSR1 310/4885 |
| US-20150352123-A1 | USE OF CAPSAZEPINE AND ANALOGS THEREOF TO TREAT CANCER | TRPV1, TRPV5, TRPA1 | TRPV1 1/4885GAA 3474/4885NPSR1 770/4885 |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | CNR1, CNR2, AVPR1A | TRPV1 9/4885GAA 2627/4885NPSR1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.